Showing results (161-170 of 188) with videos related to
Sort By:
Pageof 19
The New England Journal of Medicine|March 3, 2006
Natalizumab plus interferon beta-1a for relapsing multiple sclerosisRichard A Rudick, William H Stuart, Peter A Calabresi, et al.Neurology|September 11, 2002
Benefit of interferon beta-1a on MSFC progression in secondary progressive MSJ A Cohen, G R Cutter, J S Fischer, et al.Multiple Sclerosis and Related Disorders|October 2, 2023
Magnetic resonance fingerprinting in multiple sclerosisDaniel Ontaneda, Vikas Gulani, Anagha Deshmane, et al.Neurology|June 10, 2009
Effect of statins on clinical and molecular responses to intramuscular interferon beta-1aR A Rudick, A Pace, M R S Rani, et al.Journal of the Neurological Sciences|March 19, 2010
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosisErnst-Wilhelm Radue, William H Stuart, Peter A Calabresi, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|August 12, 2009
Assessing disability progression with the Multiple Sclerosis Functional CompositeR A Rudick, C H Polman, J A Cohen, et al.The Lancet. Neurology|April 17, 2007
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoringLudwig Kappos, David Bates, Hans-Peter Hartung, et al.Neurology|October 24, 2019
Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial dataMyla D Goldman, Nicholas G LaRocca, Richard A Rudick, et al.Brain : a Journal of Neurology|June 4, 1999
Development of a multiple sclerosis functional composite as a clinical trial outcome measureG R Cutter, M L Baier, R A Rudick, et al.European Journal of Neurology|February 4, 2020
Multiple Sclerosis Performance Test: validation of self-administered neuroperformance modulesS M Rao, R Galioto, M Sokolowski, et al.Pageof 19